Navigation Links
Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit
Date:5/25/2010

Now in its 4th year, Arrowhead's Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics.

Minneapolis, MN (PRWEB) May 25, 2010 -- The Agenda for Arrowhead’s 4th Annual Pain Therapeutics Summit, set to take place on October 4th-5th, 2010 in Philadelphia, has been announced.

Now in its 4th year, Arrowhead's Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics, regulatory issues, commercialization of new pain therapies and various other topics integral to the field of pain therapeutics.

Topics covered at this year’s Summit include:

Regulatory hurdles in pain drug development
Animal models for pain drug discovery research
Clinical development models
Trial Designs
Abuse-deterrent opioids
Long-term opioid use
Next generation therapeutics for pain
Trends in pain drug development
Preclinical and clinical activity in pain space
FDA Update
Market direction of the field of pain therapeutics
Translational pain research
Competitive landscape
Mixing basic science, drug development and clinical practice
Discovery targets: TRPV, TRPA, TRPM8, NGF antagonists, Nav1.7, P2X4, P2X7
Abuse liability and safety (REMS)
Novel mechanisms of action for future pain therapies

Speakers at this year’s event include:

Jeffrey S. Mogil, Ph.D., E.P. Taylor Chair in Pain Studies, Canada Research Chair in Genetics of Pain, McGill University

William K. Schmidt, Ph
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. FASEB Encourages NIGMS to Broaden Scientific Training Opportunities
2. Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline
3. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
4. Scientific breakthrough in genetic studies of animal domestication
5. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
6. Japan Science and Technology Agency (JST) Selects Scopus Custom Data for Citation Linkage Analysis Between Scientific Articles and Patents
7. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
8. Boston Scientific Announces Completion of $2 Billion Senior Notes Offering
9. Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum
10. Vivakor Announces Additions to Board of Directors and Scientific Advisory Board
11. Advanced Cell Technologys Chief Scientific Officer, Robert Lanza, Opening Plenary Speaker at the 3rd International Conference on Cell Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Iowa (PRWEB) September 02, 2014 Press ... of ways to take advantage of the people and ... the schedule below are available throughout the day. Additionally, ... requests with POET and DSM representatives as well as ... interview requests is appreciated. , Please remember to ...
(Date:9/2/2014)...  TransCelerate BioPharma Inc. ("TransCelerate") today announced that ... personal data in Clinical Study Reports (CSRs) that ... document describes an approach to apply when redacting ... related clinical trial documents, and is available ... TransCelerate CSR Redaction approach is to provide organizations ...
(Date:9/2/2014)... Quincy, MA (PRWEB) September 02, 2014 ... announced today the signage of a distribution agreement ... Azelis is now distributing Myriant’s bio-succinic acid in ... Kingdom and Ireland, targeting customers in the industrial ... chemical distribution powerhouse, Azelis offers a far-reaching chemical ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014 ... announced that the U.S. Patent and Trademark Office (PTO) ... investigational medication being evaluated for weight loss. NB32 is ... bupropion SR. U.S. Patent No. 8,815,889 claims ... naltrexone and bupropion. The patent expires in 2024. If ...
Breaking Biology Technology:Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... today announced positive results from its Phase IIa ... severely injured trauma patients with hemorrhagic shock causing ... given in addition to standard of care, was ... During hemorrhagic shock, inadequate perfusion of critical organs ...
... 31 Naurex Inc., a clinical stage company developing ... reported that its clinical stage candidate for the treatment ... been selected for inclusion on Windhover,s list of the ... were chosen by a committee that included Windhover Information, ...
... SEATTLE, Aug. 31 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... of Julie M. Eastland as Chief Financial Officer ... 2010. Ms. Eastland,s responsibilities will include financial management, ... Eastland brings more than 25 years of financial ...
Cached Biology Technology:Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients 2Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients 3Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch 2Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch 3Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch 4Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch 5ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER 2
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
(Date:9/1/2014)... EDT) It may be possible to train the ... foods, according to new research by scientists at the ... (USDA HNRCA) at Tufts University and at Massachusetts General ... & Diabetes , a brain scan study in adult ... reverse the addictive power of unhealthy food while also ...
Breaking Biology News(10 mins):Exceptionally well preserved insect fossils from the Rhône Valley 2Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Training your brain to prefer healthy foods 2
... inbreeding is a threat against the viabi lity of ... in the new journal PLoS ONE now demonstrates that ... expected. The results show that it is the most ... breeding population. An important consequence of this action of ...
... has discovered that some stealthy mammals have been doing something ... water. , The results of the research by Vanderbilt's Kenneth ... the science journal Nature. He became curious when he observed ... bubbles while swimming. , "This came as a ...
... which can become less effective over time, might retain ... second drug, according to new research in mice conducted ... of the National Institutes of Health, and their partners. ... of Cancer Cell*. , Tamoxifen has been used successfully ...
Cached Biology News:Wolves are suffering less from inbreeding than expected 2Contrary to common wisdom, scientist discovers some mammals can smell objects under water 2Contrary to common wisdom, scientist discovers some mammals can smell objects under water 3Restoring tamoxifen sensitivity in resistant breast cancer cells 2
Taq DNA polymerase, 10,000U...
... AmpliTaq DNA Polymerase is the ... PCR process, a testimony to its overall ... profile makes it ideal for PCR applications. ... guarantee reproducible results. ,, AmpliTaq DNA ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... GCpro Taq DNA Polymerase is a versatile ... for all PCR applications. GCpro Taq DNA ... expressed in E. coli, containing the DNA ... enzyme includes a highly processive 5'-3' DNA ...
Biology Products: